

# Special Issue

## Advances in Anal Cancer

### Message from the Guest Editors

High-risk human papillomaviruses (HPVs) are responsible for ~5% of cancers worldwide. The incidence of anal cancer and other HPV-associated anogenital cancers has been increasing in incidence. Screening programs are now more standard of practice for the precancerous lesions of anal cancer. However, it is still hard to risk stratify the resource-intensive needs of the screening and treatment.

Despite the continued rise in the incidence and mortality of squamous-cell carcinoma of the anus (SCCA). To address the increase in SCCA, we clearly need new and more effective treatments. Given the rare nature of the disease, research on this problem is limited in clinical situations. Developing an understanding of the complexity and variability of anal cancer will support the development of next-generation cancer preventative therapies and novel therapeutics to effectively control cancer development and progression, respectively. This Special Issue will highlight the role of anal cancer covering both basic, (pre)clinical aspects and clinical research that advances our understanding of this rare human tumor.

Dr. Cristina B. Sanger

---

### Guest Editors

Dr. Evie H. Carchman

1. Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
2. Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
3. William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA

Dr. Cristina B. Sanger

1. Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
2. William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA

---

### Deadline for manuscript submissions

closed (30 March 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/207622](https://mdpi.com/si/207622)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)